title: [Image-guided radiotherapy in prostate cancer: concepts and implications].
abstract: Intensity modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) are technological developments, which when applied in a model of prostate cancer, led to a significant reduction in the toxicity and digestive and urinary sequelae of 3D conformational radiotherapy. The major clinical benefits of these techniques with regard to reduced digestive and urinary toxicity are unequivocal since very few sequelae have been reported at 10 years (2% of grade 2 and 1% of grade 3 digestive toxicity; 11% of grade 2 and 5% of grade 3 urinary toxicity). Even when these two techniques are combined, IG-IMRT significantly diminishes late genitourinary toxicity. In the absence of adaptive radiotherapy, there are many IGRT protocols and repositioning techniques, and every step in the IGRT process must be carried out with extreme rigor: installing the patient and contention system, repositioning technique with or without fiduciary markers, type of repositioning imaging, definition of margins inherent in each technique (prostate, seminal vesicles and/or pelvic lymph nodes), frequency of repositioning during treatment, dietary constraints with or without rectal lavage. For these reasons, every centre that performs IGRT must carefully and rigorously assess the uncertainties of repositioning linked to the IGRT technique. In this review, we analyzed data from the literature based on dosimetric studies and the proven clinical impact in order to answer the different questions asked by radiation oncologists at every step of the IGRT process for cancer of the prostate. Recommendations are made for the repositioning protocols according to the most widely used repositioning techniques: fiduciary markers or soft tissues, kV-CBCT or MV-CBCT, 3D ultrasonography.
authors.affiliation: Département de radiothérapie, centre Georges-François-Leclerc, Dijon, France. gcrehange@cgfl.fr
authors.forename: G
authors.initials: G
authors.lastname: Créhange
authors.forename: E
authors.initials: E
authors.lastname: Martin
authors.forename: S
authors.initials: S
authors.lastname: Supiot
authors.forename: O
authors.initials: O
authors.lastname: Chapet
authors.forename: F
authors.initials: F
authors.lastname: Mazoyer
authors.forename: S
authors.initials: S
authors.lastname: Naudy
authors.forename: P
authors.initials: P
authors.lastname: Maingon
mesh_terms: D004032:Diet; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects; D008297:Male; D056888:Patient Positioning; D010388:Pelvis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D019736:Prostheses and Implants; D018714:Radiotherapy, Adjuvant; D061089:Radiotherapy, Image-Guided; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods